Nuclear Medicine and Biology
Volume 37, Issue 2 , Pages 205-214 , February 2010

High-resolution imaging of brain 5-HT1B receptors in the rhesus monkey using [11C]P943

  • Nabeel Nabulsi

      Affiliations

    • Yale PET Center, Department of Diagnostic Radiology and Psychiatry, Yale University School of Medicine, P.O. Box 208048, New Haven, CT 06520-8048, USA
    • Current address: Kreitchman PET Center, Columbia University Medical Center, New York, NY.
    • ,
  • Yiyun Huang

      Affiliations

    • Yale PET Center, Department of Diagnostic Radiology and Psychiatry, Yale University School of Medicine, P.O. Box 208048, New Haven, CT 06520-8048, USA
    • ,
  • David Weinzimmer

      Affiliations

    • Yale PET Center, Department of Diagnostic Radiology and Psychiatry, Yale University School of Medicine, P.O. Box 208048, New Haven, CT 06520-8048, USA
    • ,
  • Jim Ropchan

      Affiliations

    • Yale PET Center, Department of Diagnostic Radiology and Psychiatry, Yale University School of Medicine, P.O. Box 208048, New Haven, CT 06520-8048, USA
    • ,
  • James J. Frost

      Affiliations

    • Yale PET Center, Department of Diagnostic Radiology and Psychiatry, Yale University School of Medicine, P.O. Box 208048, New Haven, CT 06520-8048, USA
    • ,
  • Timothy McCarthy

      Affiliations

    • Pfizer Global R&D, Groton, CT 06340, USA
    • ,
  • Richard E. Carson

      Affiliations

    • Yale PET Center, Department of Diagnostic Radiology and Psychiatry, Yale University School of Medicine, P.O. Box 208048, New Haven, CT 06520-8048, USA
    • ,
  • Yu-Shin Ding

      Affiliations

    • Yale PET Center, Department of Diagnostic Radiology and Psychiatry, Yale University School of Medicine, P.O. Box 208048, New Haven, CT 06520-8048, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 203 785 4297; fax: +1 203 785 3107.

Received 16 August 2009 ,Revised 16 October 2009 ,Accepted 23 October 2009.

References 

  1. Miller HE, Deakin JF, Anderson IM. Effect of acute tryptophan depletion on CO2-induced anxiety in patients with panic disorder and normal volunteers. Br J Psychiatry. 2000;176:182–188
  2. Graeff FG, Guimaraes FS, De Andrade TG, Deakin JF. Role of 5-HT in stress, anxiety, and depression. Pharmacol Biochem Behav. 1996;54:129–141
  3. Zohar J, Mueller EA, Insel TR, Zohar-Kadouch RC, Murphy DL. Serotonergic responsivity in obsessive-compulsive disorder. Comparison of patients and healthy controls. Arch Gen Psychiatry. 1987;44:946–951
  4. Deakin JF, Pennell I, Upadhyaya AJ, Lofthouse R. A neuroendocrine study of 5HT function in depression: evidence for biological mechanisms of endogenous and psychosocial causation. Psychopharmacology (Berl). 1990;101:85–92
  5. Meltzer HY, Li Z, Kaneda Y, Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27:1159–1172
  6. Svenningsson P, Chergui K, Rachleff I, Flajolet M, Zhang X, Yacoubi ME, et al. Alterations in 5-HT1B receptor function by p11 in depression- like states. Science. 2006;311:77–80
  7. Engel G, Göthert M, Hoyer D, Schlicker E, Hillenbrand K. Identity of inhibitory presynaptic 5-hydroxytryptamine (5-HT) autoreceptors in the rat brain cortex with 5-HT1B binding sites. Naunyn Schmiedebergs Arch Pharmacol. 1986;332:1–7
  8. Smoller JW, Biederman J, Arbeitman L, Doyle AE, Fagerness J, Perlis RH, et al. Association between the 5HT1B receptor gene (HTR1B) and the inattentive subtype of ADHD. Biol Psychiatry. 2006;59:460–467
  9. Huang Y, Oquendo MA, Harkavy Friedman JM, Greenhill LL, Brodsky B, Malone KM, et al. Substance abuse disorder and major depression are associated with the human 5-HT1B receptor gene (HTR1B) G861C polymorphism. Neuropsychopharmacology. 2003;28:163–169
  10. Quist JF, Barr CL, Schachar R, Roberts W, Malone M, Tannock R, et al. The serotonin 5-HT1B receptor gene and attention deficit hyperactivity disorder. Mol Psychiatry. 2003;8:98–102
  11. Halazy S, Lamothe M, Jorand-Lebrun C. 5-HT1B/1D antagonists and depression. Exp Opin Ther Patents. 1997;7:339–352
  12. López-Figueroa AL, Norton CS, López-Figueroa MO, Armellini-Dodel D, Burke S, Akil H, et al. Serotonin 5-HT1A, 5-HT1B, and 5-HT2A receptor mRNA expression in subjects with major depression, bipolar disorder, and schizophrenia. Biol Psychiatry. 2004;1(55):225–233[Erratum in: Biol Psychiatry 2004;55:660]
  13. Stenfors C, Hallerbäck T, Larsson LG, Wallsten C, Ross SB. Pharmacology of a novel selective 5-hydroxytryptamine1B receptor antagonist, AR-A000002. Naunyn Schmiedebergs Arch Pharmacol. 2004;369:330–337
  14. Hudzik TJ, Yanek M, Porrey T, Evenden J, Paronis C, Mastrangelo M, et al. Behavioral pharmacology of AR-A000002, a novel, selective 5-hydroxy- tryptamine1B antagonist. J Pharmacol Exp Ther. 2003;304:1072–1084
  15. McCarthy TJ, Hoglund U, Antoni G, Lindhe O, Sobolov S, Gray P, et al. Discovery and qualification of the first selective 5-HT1B PET radiotracer using a novel PET radiotracer development paradigm. In: Presented at the Joint Molecular Imaging Conference, September 8–11 2007, Providence, Rhode Island, USA. 2007;(JMIC Abstract Book, Presentation #0985, p362)
  16. Helal CJ, Gunnar A, Langstrom B, Sheng, JZ, Jaynes-sobolov S, Mccarthy T. 11C-Labeled Benzyl-Lactam Compounds and Their Use as Imaging Agents. U.S. Patent 0 206 137, 2008.
  17. Larsen P, Ulin J, Dahlstrom K, Jensen M. Synthesis of [11C]iodomethane by iodination of [11C]methane. Appl Radiat Isot. 1997;48:153–157
  18. Jewett D. A simple synthesis of [11C]methyl triflate. Appl Radiat Isot. 1992;43:1383–1385
  19. The silver triflate column was prepared by modifying literature procedure [18]. Briefly, 60 g of graphpac-GC (Alltech, uncoated, 80/100) was added to a solution of 25 g of silver trifluromethanesulfonate in 50 mL of anhydrous acetonitrile. The resulting heterogeneous mixture was mixed well and then the solvent was slowly evaporated to dryness (Technical Notes).
  20. de Jong HW, van Velden FH, Kloet RW, Buijs FL, Boellaard R, Lammertsma AA. Performance evaluation of the ECAT HRRT: an LSO-LYSO double layer high resolution, high sensitivity scanner. Phys Med Biol. 2007;52:1505–1526
  21. Carson RE, Barker WC, Liow JS, Adler S, Johnson CA. Design of a motion-compensation OSEM List-mode Algorithm for Resolution-Recovery Reconstruction of the HRRT. In: Conf Record IEEE Nuclear Science Symposium and Medical Imaging Conference. 2003;p. M1–M16[Portland, OR]
  22. Carson RE, Channing MA, Blasberg RG, Dunn BB, Cohen RM, Rice KC, et al. Comparison of bolus and infusion methods for receptor quantitation: application to [18F]cyclofoxy and positron emission tomography. J Cereb Blood Flow Metab. 1993;3:24–42
  23. Tomasi G, Nabulsi N, Weinzimmera D, Sandiego C, Gallezot JD, Wang E, et al. In vivo Scatchard analysis of bolus/infusion 5-HT1B studies with [C-11]P943: Comparison between SRTM and equilibrium methods. Neuroimage. 2008;41:T16
  24. Pierson ME, Andersson J, Nyberg S, McCarthy DJ, Finnema SJ, Varnäs K, et al. Halldin C. [11C]AZ10419369: a selective 5-HT1B receptor radioligand suitable for positron emission tomography (PET). Characterization in the primate brain. Neuroimage. 2008;41:1075–1085
  25. Olivier B, van Oorschot R. 5-HT1B receptors and aggression: a review. Eur J Pharmacol. 2005;526:207–217
  26. Barnes NM, Sharp TA. Review of central 5-HT receptors and their function. Neuropharmacology. 1999;38:1083–1152
  27. Pauwels PJ, Colpaert FC. Selective antagonism of human 5-HTlD and 5-HT1B receptor- mediated responses in stably transfected C6-glial cells by ketanserin and GR 127,935. European J Pharmacology. 1996;300:141–145
  28. Rousselle JC, Plantefol M, Fillion MP, Massot O, Pauwels PJ, Fillion G. Specific interaction of 5-HT-moduline with human 5-HT1bas well as 5-HT1d receptors expressed in transfected cultured cells. Naunyn-Schmiedeberg's Arch Pharmacol. 1998;358:279–286
  29. De Vries P, Willems EW, Heiligers JP, Villalón CM, Saxena PR. Investigation of the role of 5-HT1B and 5-HT1D receptors in the sumatriptan-induced constriction of porcine carotid arteriovenous anastomoses. Br J Pharmacol. 1999;127:405–412
  30. Hoyer D, Hannon JP, Martin GR. Molecular, pharmacological and functional diversity of 5- HT receptors. Pharmacol Biochem Behav. 2002;71:533–554
  31. Varnäs K, Hurd YL, Hall H. Regional expression of 5-HT1B receptor mRNA in the human brain. Synapse. 2005;56:21–28
  32. Varnäs K, Hall H, Bonaventure P, Sedvall G. Autoradiographic mapping of 5-HT1B and 5- HT1D receptors in the post mortem human brain using [3H]GR 125743. Brain Res. 2001;915:47–57
  33. Varnäs K, Halldin C, Hall H. Autoradiographic distribution of serotonin transporters and receptor subtypes in human brain. Hum Brain Mapp. 2004;22:246–260
  34. Hall H, Lundkvist C, Halldin C, Farde L, Pike VW, McCarron JA, et al. Autoradiographic localization of 5-HT1A receptors in the post- mortem human brain using [3H]WAY-100635 and [11C]way-100635. Brain Res. 1997;745:96–108
  35. Nabulsi N, Huang Y, Ropchan J, Cosgrove KP, Staley J, Planta-Wilson B, et al. Synthesis and evaluation of [11C]P943 for 5- HT1B receptor studies in primates and humans. In: Presented at the Joint Molecular Imaging Conference, September 8–11 2007, Providence, Rhode Island, USA. 2007;(JMIC Abstract Book, Presentation #0155, p74)
  36. Kim SH, Neumeister A, Planeta-Wilson B, Gallezot JD, McCarthy T, Nabulsi N, et al. High resolution imaging of brain serotonin 5-HT1B receptors using [C-11]943 and the HRRT PET scanner. In: Presented at the Joint Molecular Imaging Conference, September 8–11 2007, Providence, Rhode Island, USA. 2007;(JMIC Abstract Book, Presentation #0137, p65)
  37. Gallezot JD, Nabulsi N, Neumeister A, Planeta-Wilson B, Williams WA, Singhal T, et al. Kinetic modeling of the serotonin 5 HT1B receptor radioligand [11C]P943 in humans. J Cereb Blood Flow Metab. 2009;[Epub, (in press)]
  38. Carson RE, Nabulsi N, Weinzimmer D, Sandiego CM, Gallezot JD, Wang E, et al. Scatchard analysis of 5-HT1B receptors with [11C]P943 in non-human primates. J Nucl Med. 2007;49(Suppl 1):79P
  39. Scott C, Langmead CJ, Clarke KL, Wyman P, Smith PW, Starr KR, et al. SB-616234-A (1-[6-(cis-3,5-dimethylpiperazin-1-yl)-2,3-dihydro-5- methoxyindol-1-yl]-1-[2′methyl-4′-(5-methyl-1,2,3-oxadiazol-3-yl)biphenyl-4-yl]methanone hydrochloride): a novel, potent and selective 5-HT1B receptor antagonist. Neuropharmacology. 2006;50:984–990
  40. Dawson LA, Hughes ZA, Starr KR, Storey JD, Bettelini L, Bacchi F, et al. Characterisation of the selective 5-HT1B receptor antagonist SB-616234-A (1-[6-(cis-3,5-dimethylpiperazin-1-yl)-2,3-dihydro-5- methoxyindol-1-yl]-1-[2′-methyl-4′-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4- yl]methanone hydrochloride): in vivo neurochemical and behavioural evidence of anxiolytic/antidepressant activity. Neuropharmacology. 2006;50:975–983

PII: S0969-8051(09)00255-8

doi: 10.1016/j.nucmedbio.2009.10.007

Nuclear Medicine and Biology
Volume 37, Issue 2 , Pages 205-214 , February 2010

Article Tools

* Image Usage & Resolution